A Synthetic Thiourea-Based Tripodal Receptor that Impairs the Function of Human First Trimester Cytotrophoblast Cells

International Journal of Environmental Research and Public Health

Darijana Horvat²  Maryam Emami Khansari¹  Avijit Pramanik¹  Madhava R. Beeram³  Thomas J. Kuehl²  Md. Alamgir Hossain¹ 

[1] Department of Chemistry and Biochemistry, Jackson State University, Jackson, MS 39217, USA; E-Mails:;Department of Obstetrics & Gynecology, Texas A&M Health Science Center College of Medicine/Scott & White Hospital, Temple, TX 76508, USA; E-Mails:;Department of Pediatrics, Texas A&M Health Science Center College of Medicine/Scott & White Hospital, Temple, TX 76508, USA; E-Mail:

关键词: angiogenic;    cardiotonic steroids;    cell signaling;    cytotrophoblast;    preeclampsia;    thiourea;   

DOI  :  10.3390/ijerph110707456

来源: mdpi

【 摘 要 】

A synthetic tripodal-based thiourea receptor (PNTTU) was used to explore the receptor/ligand binding affinity using CTB cells. The human extravillous CTB cells (Sw.71) used in this study were derived from first trimester chorionic villus tissue. The cell proliferation, migration and angiogenic factors were evaluated in PNTTU-treated CTB cells. The PNTTU inhibited the CTBs proliferation and migration. The soluble fms-like tyrosine kinase-1 (sFlt-1) secretion was increased while vascular endothelial growth factor (VEGF) was decreased in the culture media of CTB cells treated with ≥1 nM PNTTU. The angiotensin II receptor type 2 (AT₂) expression was significantly upregulated in ≥1 nM PNTTU-treated CTB cells in compared to basal; however, the angiotensin II receptor, type 1 (AT₁) and vascular endothelial growth factor receptor 1 (VEGFR-1) expression was downregulated. The anti-proliferative and anti-angiogenic effect of this compound on CTB cells are similar to the effect of CTSs. The receptor/ligand affinity of PNTTU on CTBs provides us the clue to design a potent inhibitor to prevent the CTS-induced impairment of CTB cells.

【 授权许可】

CC BY   
© 2014 by the authors; licensee MDPI, Basel, Switzerland.